[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619332":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":11,"centralContacts":11,"locations":48,"responsibleParty":65,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":11,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY",[8,15,18,22,25,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1, A","EXPERIMENTAL",null,[13,14],"Drug: DW4421","Drug: DW4421-N1",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 1, B",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort 2, C",[13,21],"Drug: DW4421-N2",{"label":23,"type":10,"description":11,"interventionNames":24},"Cohort 2, D",[13,21],{"label":26,"type":10,"description":11,"interventionNames":27},"Cohort 3, E",[13,28],"Drug: DW4421-N3",{"label":30,"type":10,"description":11,"interventionNames":31},"Cohort 3, F",[13,28],[33,38,42,45],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DRUG","DW4421","QD",[9,16,19,23,26,30],{"type":34,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"DW4421-N1","BID",[9,16],{"type":34,"name":43,"description":40,"armGroupLabels":44,"otherNames":11},"DW4421-N2",[19,23],{"type":34,"name":46,"description":36,"armGroupLabels":47,"otherNames":11},"DW4421-N3",[26,30],[49],{"facility":50,"status":51,"city":52,"state":11,"zip":11,"country":53,"countryCode":11,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Chungbuk National University Hospital","RECRUITING","Cheongju-si","South Korea",{"type":55,"coordinates":56},"Point",[57,58],127.48972,36.63722,{"lat":58,"lon":57},[61],{"name":50,"role":62,"phone":63,"phoneExt":11,"email":64},"CONTACT","+82-43-269-6771","cbnuhirb@naver.com",{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619332","phase-1-a-phase-1-clinical-trial-to-evaluate-the-safety-and-ddi-of-dw4421-and-3-nsaids-100619332",false,"NCT07343245","A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics Drug-Drug Interaction of DW4421 and 3 NSAIDs in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history",true,"ALL","19 Years","50 Years",{"count":79,"type":80},150,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs",[86],"Healthy Adult","2026-01-06",{"date":89,"type":90},"2026-01-15","ACTUAL",{"date":92,"type":90},"2025-12-01",{"date":94,"type":80},"2026-06-17",{"name":5,"class":6},1]